Regeneron stock trades at EUR 709.80 ahead of October 30 results

Published on 10/19/2026 at 10:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Regeneron stock costs EUR 709.80 on October 19, 2026 ahead of October 30 results. Second-quarter revenue rose 16.70 percent to USD 4.29 billion.

Results and clinical milestones

Pasatru produced zero new lesions versus 9 for placebo at week 84 on October 12, 2026.
Second-quarter 2026 revenue rose 16.70 percent to USD 4.29 billion.
Regeneron stock trades at EUR 709.80 at 10:05 a.m. CEST at Lang & Schwarz on October 19, 2026.
Regeneron will report third-quarter results on October 30, 2026.

Makroaufnahme einer transparenten Antikörper-Proteinstruktur in Blau- und Weißtönen — Regeneron Pharma US75886F1075 fokussiert eine detailreiche Makroaufnahme einer transparenten Antikörper-Proteinstruktur mit feinen Lichtreflexen, Illustration mit AI erstellt.

Regeneron stock was trading at EUR 709.80 at Lang & Schwarz on October 19, 2026, at 10:05 a.m. CEST. The company will report third-quarter 2026 results on October 30, a date announced by Regeneron.

Quarterly growth sets the baseline

Regeneron reported second-quarter 2026 revenue of USD 4.29 billion, up 16.70 percent from USD 3.68 billion a year earlier, according to Investing.com. The same report listed adjusted earnings per share of USD 14.29, compared with a USD 10.16 consensus estimate, giving the upcoming report a demanding comparison base.

Three dates explain the setup

On July 30, 2026, second-quarter revenue reached USD 4.29 billion, according to Investing.com. On October 8, 2026, RBC Capital maintained a Hold rating with a USD 810.00 target, while Raymond James maintained Buy with a USD 911.00 target, also reported by Investing.com. On October 12, 2026, Regeneron's Pasatru trial extension showed zero new heterotopic ossification lesions from week 56 to week 84, versus 9 for placebo, in an official Regeneron release.

What does the next report mean?

The October 30 release will show whether the USD 4.29 billion second-quarter revenue base and USD 14.29 adjusted earnings per share can be extended. Regeneron's market capitalization stood at USD 81.4 billion on October 16, 2026, while its Nasdaq 52-week range was USD 572.75 to USD 859.34.

October 30 is the next date

The next substantiated company date is October 30, 2026, when Regeneron will publish third-quarter financial and operating results before U.S. markets open and host an 8:30 a.m. ET conference call, according to Regeneron.

Stock price and valuation context

At EUR 709.80, the Lang & Schwarz quote gives investors a euro-denominated reference before the scheduled results. The primary listing is on Nasdaq, where the October 16, 2026 quote was USD 790.74 and the 52-week high was USD 859.34.

The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.